

doi: 10.13241/j.cnki.pmb.2017.07.023

冠心病患者胰岛素抵抗程度的影响因素分析 *

李 松 江 倩 彭 丹 覃松柏 王永贞

(湖北中医药大学附属荆州市中医医院 心病科 湖北 荆州 434000)

摘要 目的:分析冠心病患者胰岛素抵抗程度的影响因素。**方法:**选择我院收治的冠心病住院患者 166 例,根据胰岛素抵抗指数(HOMA-IR)水平将其分成四组。A 组:HOMA-IR≤ 1.53(n=36);B 组:1.53 < HOMA-IR≤ 3.46(n=30);C 组:3.46 < HOMA-IR≤ 5.13(n=36);D 组:HOMA-IR≥ 5.14(n=64)。检测和比较各组一般临床资料和相关生化指标的差异,并进一步分析影响冠心病患者胰岛素抵抗程度的危险因素。**结果:**C、D 组腰围、空腹血糖(FBG)、餐后 2 h 血糖(2 hPBG)、低密度脂蛋白胆固醇(LDL-C)均高于 A、B 组;D 组空腹胰岛素(INS)均高于 A、B 组,B、C 组 INS、LDL-C 均高于 A 组;D 组体质指数、TC 高于 A 组。上述差异均有统计学意义($P < 0.05$)。多因素分析结果显示 BMI、腰臀比(WHR)、FBG、INS、TC、HDL-C 均是 HOMA-IR 的影响因素($P < 0.05$)。**结论:**体重、腰围、FBG、2hPBG、INS、TC、HDL-C 的上升均为加重冠心病患者胰岛素抵抗程度的危险因素。

关键词:冠心病;胰岛素抵抗;危险因素;分布特点

中图分类号:R541.4 文献标识码:A 文章编号:1673-6273(2017)07-1294-03

Analysis of the Distribution Characteristics of Various Risk Factors in Patients with Coronary Heart Disease in Patients with Different Levels of Insulin Resistance*

LI Song, JIANG Qian, PENG Dan, QIN Song-bai, WANG Yong-zhen

(Department of Cardiology, Jingzhou traditional Chinese Medicine Hospital Affiliated to Hubei University of traditional Chinese Medicine, Jingzhou, Hubei, 434000, China)

ABSTRACT Objective: To study the distribution characteristics of multiple risk factors in patients with coronary heart disease in patients with different levels of insulin resistance. **Methods:** 166 cases of hospitalized patients with coronary heart disease in our hospital, according to insulin resistance index (HOMA-IR) level will be divided into four groups: group A: HOMA-IR was less than or equal to 1.53 (n=36); group B: 1.53 < HOMA-IR was less than or equal to 3.46 (n=30); group C 3.46 < HOMA-IR was less than or equal to 5.13 (n=36); group D: HOMA-IR was more than or equal to 5.14 (n=64). Used the stable model assessment insulin resistance level of coronary heart disease risk factors distribution. **Results:** C and D group's waist circumference, FBG, 2hPBG, LDL-C were higher than B, D group INS were higher than B, B group, INS, C group LDL-C, D group, A group, TC higher than A group. The difference was statistically significant (BMI, WHR, INS, TC, HDL-C, HOMA-IR) were statistically significant ($P < 0.05$). Weight, waist circumference, 2hPBG, TC, HDL-C, INS were increased in patients with coronary heart disease and insulin resistance in hospitalized patients with FBG. **Conclusion:** Body weight, waist circumference, FBG, 2hPBG, INS, TC, and HDL-C are all increased in patients with coronary heart disease and insulin resistance.

Key words: Coronary heart disease; Insulin resistance; Risk factors; Distribution characteristics

Chinese Library Classification(CLC): R541.4 Document code: A

Article ID: 1673-6273(2017)07-1294-03

前言

冠心病是临幊上常见的心血管疾病之一^[1]。近年来,随着人们生活方式与饮食结构的改变,该病的发病率呈逐年增高,严重影响患者的生活质量。临床研究显示冠心病和 2 型糖尿病常相伴而行,具有胰岛素抵抗的患者冠心病发病率更高^[2]。近年来有研究表明^[3,4]胰岛素抵抗是冠心病等心血管疾病的病理生理基础,也是冠心病发病的强力预测因素。然而,不同胰岛素抵抗

水平的患者冠心病发病情况如何仍缺乏有关报道^[5]。为了能进一步了解冠心病患者不同胰岛素抵抗水平下多种危险因素的分布特点,本研究选取了 168 例冠心病住院患者进研究,现将结果报道如下。

1 资料和方法

1.1 临床资料

选择 2012 年 9 月~2014 年 9 月在我院住院的冠心病患

* 基金项目:湖北省自然科学基金项目(2003ABA183)

作者简介:李松(1983-),男,硕士,主治医师,主要从事心血管方面的研究,电话:13797365907

(收稿日期:2016-05-27 接受日期:2016-06-14)

者 168 例作为研究对象。入选标准:①符合 WHO 制定的冠心病诊断标准^[6];②知情同意并自愿接受本次研究。排除标准:①合并糖尿病、严重肝肾疾病者;②近期内服用胰岛素治疗者。其中,男 108 例,女 58 例;年龄 49~76 岁,平均(54.9±10.5)岁;心肌梗死 64 例,心绞痛 76 例,心肌缺血 26 例。

1.2 研究方法

所有患者在入院一周内,禁食 12 h 后,于次日清晨抽取空腹静脉血,之后口服葡萄糖 75 g,采集 2 h 后的静脉血。测定其空腹血糖(FBG)、餐后 2 h 血糖(2hPBG)、空腹胰岛素(INS)、餐后 2 h 胰岛素(2hINS)、空腹总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、脂蛋白 α(LP-α)、三酰甘油(TG)、血尿酸(UA)、谷胺酰氨转肽酶(GGT)等含量。其中,血糖和胰岛素水平统一采用酶法测定;通过 Friedewald 公式计算 LDL-C=(TC-HDL-C-TG)/2.2。根据数学模型稳定模式评估法计算 HOMA-IR=(FBG×INS)/22.5。参考 HOMA-IR 结果将 168 例患者分成四个组,A 组:HOMA-IR≤1.53(n=36);B 组:1.53<

HOMA-IR≤3.46(n=30);C 组:3.46< HOMA-IR≤5.13(n=36);D 组:HOMA-IR≥5.14(n=64),为冠心病胰岛素抵抗组。并计算各组患者的体质质量指数(BMI)=体质质量 / 身高平方;腰臀比(WHR)=腰围 / 臀围。

1.3 统计学分析

数据以 SPSS20.0 统计软件分析。计数资料采用(%)比较进行 χ^2 检验;计量资料采用($\bar{x} \pm s$)比较,配对进行 t 检测;多因素分析 Logistic 回归分析。以 P<0.05 为差异有统计学意义。

2 结果

2.1 各组一般资料比较

D 组患者体质质量明显重于 A 组,C、D 组患者腰围均大于 A、B 组,差异均有统计学意义(P<0.05)。四组间在性别、年龄、BMI 及 WHR 方面上比较,差异均无统计学意义(P>0.05)。见表 1。

表 1 各组一般资料比较($\bar{x} \pm s$)

Table 3 Comparison of the general data between different groups ($\bar{x} \pm s$)

Facts	Group A(n=36)	Group B(n=30)	Group C(n=36)	Group D(n=64)
male(n, %)	24(66.67)	20(66.67)	23(63.89)	41(64.06)
age(year)	55.6±10.2	56.1±10.2	53.9±10.4	54.2±10.3
weight(kg)	70.5±11.8	72.4±12.3	72.8±11.9	75.9±12.7 ^{①②}
BMI(kg/m ²)	25.8±3.5	26.2±3.7	26.4±3.5	26.7±3.3
waistline(cm)	92.9±8.4	93.8±9.3	97.1±9.5 ^①	96.8±10.6 ^{①②}
WHR	0.93±0.06	0.96±0.08	0.97±0.07	1.05±0.09

Note: compared with group A,^①P<0.05; compared with group B,^②P<0.05.

2.2 各组相关生化指标比较

C、D 组患者 FBG、2hPBG、LDL-C 均明显高于 A、B 组;D 组患者 INS 高于 A、B 组,B、C 组 INS、LDL-C 高于 A 组;D 组

患者 TC 高于 A 组,差异均有统计学意义(P<0.05)。四组间在 2hINS、HDL-C、LP-α、TG、UA 及 GGT 含量比较,差异均无统计学意义(P>0.05)。见表 2。

表 2 各组相关生化指标比较($\bar{x} \pm s$)

Table 2 Comparison of the biochemical indexes between different groups ($\bar{x} \pm s$)

Facts	Group A(n=36)	Group B(n=30)	Group C(n=36)	Group D(n=64)
FBG(mmol/L)	5.2±1.6	5.3±2.0	7.3±3.2 ^{①②}	8.4±3.4 ^{①②}
2hPBG(mmol/L)	10.2±4.7	11.1±6.9	15.3±5.7 ^{①②}	17.0±6.2 ^{①②}
INS(mU/L)	6.2±2.1	12.4±3.1 ^①	15.6±5.6 ^①	25.9±9.6 ^{①②}
2hINS(mU/L)	71.7±50.6	72.9±45.7	76.5±51.3	75.3±50.0
TC(mmol/L)	4.0±0.9	4.3±1.2	4.6±0.8	4.7±1.2 ^①
LDL-C(mmol/L)	2.2±0.9	2.5±0.8 ^①	2.8±0.7 ^{①②}	3.0±1.0 ^{①②}
HDL-C(mmol/L)	1.2±0.4	1.1±0.3	1.1±0.3	1.2±0.3
LP-α(mg/L)	156.5±74.1	165.3±90.1	166.1±91.5	162.4±98.3
TG(mmol/L)	2.1±1.3	2.3±1.2	2.6±1.4	2.8±1.5
UA(μmol/L)	279.3±75.4	296.8±71.8	285.4±73.5	287.4±92.6
GGT(IU/L)	31.6±20.4	28.5±20.1	33.2±22.2	28.4±20.9

Note: compared with group A,^①P<0.05; compared with group B,^②P<0.05.

2.3 HOMA-IR 水平与冠心病危险因素的相关性分析

以 HOMA-IR 作为因变量,年龄、BMI、WHR、FBG、INS、TC、LDL-C、HDL-C 以及 TG 作为自变量进行多因素线性回归分析。可知,BMI、WHR、FBG、INS、TC、HDL-C 均是 HOMA-IR

的影响因素,见表 3。

3 讨论

冠心病作为一种心脑血管疾病,现已发展成严重危害人类

表 3 HOMA-IR 水平与冠心病危险因素相关分析
Table 3 Correlation between HOMA-IR level and risk factors of coronary heart disease

Statistic	Age	BMI	WHR	FBG	INS	TC	LDL-C	HDL-C	TG
r value	-0.042	0.303	0.324	0.365	0.394	0.311	0.124	-0.301	0.163
P value	0.735	0.025*	0.020*	0.009*	0.005*	0.021*	0.412	0.024*	0.230

身体健康主要疾病之一^[7,8]。相关研究表明^[9]胰岛素抵抗是冠心病的强力预测因素，并且与冠心病其他危险因素有着密切关系。胰岛素抵抗是胰岛素促进葡萄糖摄取和利用的生物反应下降，进而刺激β细胞释放过多的胰岛素，从而引发高胰岛素血症的状态^[10]。大量研究证实^[11-13]发生此反应的主要原因是胰岛素受体缺陷或其功能受损。胰岛素抵抗还会直接引起动脉粥样硬化及糖脂代谢紊乱等发生，使机体凝血异常，从而促进冠心病病情的进展^[15]。因此，探析冠心病患者不同胰岛素抵抗水平下多种危险因素的分布特点，对冠心病的诊断和治疗具有重要意义。

本研究通过对 168 例冠心病住院患者进行发现，结果显示 HOMA-IR 水平较高者，其体质量与腰围相对较大，说明随着胰岛素抵抗程度的加剧，冠心病患者的体质量与腰围也会增加，符合马红红等报道结果^[16]，这可能是因为体重、腰围超过正常标准会促进胰岛素抵抗的进展。对于肥胖患者而言，其胰岛素受体数量相对减少，因而易影响葡萄糖的利用度。此外，HOMA-IR 水平较高者，其 FBG、2hPBG、INS、TC、HDL-C 也相对较高。与 Peter Willeit 等报道结果基本一致^[17]，表明随着胰岛素抵抗程度的加重，冠心病患者的空腹血糖、餐后 2 h 胰岛素、空腹胰岛素、空腹总胆固醇以及高密度脂蛋白胆固醇的含量逐步增高。虽然 TG 也呈上升趋势，但变化并不明显。究其原因可能是因为胰岛素抵抗与血脂、脂蛋白代谢异常存在着一定的正相关性，当胰岛素抵抗进展加剧时，血脂代谢异常亦加剧。同时作为胰岛素抵抗的一项代偿机制 - 高胰岛素血症，可以提高机体内肝脏酯酶的活性，将 HDL-C 分解成小颗粒的 LDL-C，从而在整体上降低 HDL-C 的浓度^[18]。因此，胰岛素与脂代谢异常共同加速这冠心病的发生。HOMA-IR 与冠心病危险因素的相关性分析结果显示 BMI、WHR、FBG、INS、TC、HDL-C 均是 HOMA-IR 的独立危险因素，说明胰岛素抵抗与上述因素相互作用，互为因果。Yanwen Qin 等研究报道^[19]小时年龄是胰岛素抵抗的影响因素，而本研究中并未得到此结果，这可能是因为本研究中将合并高血压与糖尿病的冠心病患者排除在外，而此类疾病的发生率随年龄增长而增加^[20]。

综上所述，体重、腰围、FBG、2hPBG、INS、TC、HDL-C 的上升均是冠心病合并胰岛素抵抗住院患者的主要分布特点。此类患者应严格地控制自己的饮食习惯、保持良好的生活方式。

参考文献(References)

- 周广朋, 张景岚, 陈树, 等. 冠心病合并 II 型糖尿病患者脂联素与胰岛素受体的表达水平及临床意义 [J]. 西部医学, 2015, 27(10): 1494-1496
Zhou Guang-peng, Zhang Jing-lan, Chen Shu, et al. The expression level and clinical significance of adiponectin and insulin receptor in patients with coronary heart disease complicated with type II diabetes [J]. western medicine, 2015, 27(10): 1494-1496
- Amr Hany, Metwally Mohamed-Adel F, Elgamal. The relation between hepatitis C virus and coronary heart disease [J]. Medical hypotheses, 2014, 82(4): 505-506
- 鹿小燕. 基于胰岛素抵抗代谢综合征及冠心病中医干预研究思路探讨[J]. 中西医结合心脑血管病杂志, 2013, 11(6): 746-747
Lu Xiao-yan. Based on insulin resistance and metabolic syndrome and coronary heart disease with TCM Intervention Research[J]. Combination of Chinese traditional and Western Medicine Journal of cardiovascular and cerebrovascular disease, 2013, 11(6): 746-747
- 付常宁, 靳奇峰, 王彦富, 等. 胰岛素抵抗和血清 IL-18 水平与冠心病斑块纤维帽厚度负相关[J]. 细胞与分子免疫学杂志, 2015, 31(4): 537-539
Fu Chang-ning, Jin Qi-feng, Wang Yan-fu, et al. Insulin resistance and serum levels of IL-18 and coronary plaque fibrous cap thickness negative correlation [J]. Cellular and molecular immunology magazine, 2015, 31(4): 537-539
- Emily Mt, Padhi Heather J, Blewett Alison M, et al. Whole Soy Flour Incorporated into a Muffin and Consumed at 2 Doses of Soy Protein Does Not Lower LDL Cholesterol in a Randomized, Double-Blind Controlled Trial of Hypercholesterolemic Adults [J]. The Journal of nutrition, 2015, 145(12): 2665-2674
- Tomokazu, Iguchi Takao, Hasegawa Kenichiro, et al. Insulin resistance is associated with coronary plaque vulnerability: insight from optical coherence tomography analysis[J]. European heart journal cardiovascular Imaging, 2014, 15(3): 284-291
- 李刚, 陈旸, 周广朋. 冠心病患者胰岛素受体的表达水平及临床意义 [J]. 中国心血管杂志, 2014, 19(3): 185-187
Li Gang, Chen Yang, Zhou Guang-peng. The expression level and its clinical significance of insulin receptor in patients with coronary heart disease[J]. Chinese Journal of cardiovascular, 2014, 19(3): 185-187
- Danit, Ariel Gerald, Reaven. Modulation of coronary heart disease risk by insulin resistance in subjects with normal glucose tolerance or pre-diabetes[J]. Acta diabetologica, 2014, 51(6): 1033-1039
- 楚新梅, 何秉贤, 吴永健, 等. 乌鲁木齐市维吾尔族、汉族住院患者胰岛素抵抗状态下多种危险因素分析 [J]. 中国动脉硬化杂志, 2015, 23(3): 281-284
Chu Xin-mei, He Bing-xian, Wu Yong-jian, et al. Urumqi City, Multiple risk factors analysis of Uygur and Han hospitalized patients with insulin resistance [J]. Chinese Journal of arteriosclerosis, 2015, 23(3): 281-284
- 马红红, 马艳梅. 不同胰岛素抵抗状况下冠心病患者的影响因素分析 [J]. 医学临床研究, 2015, 32(9): 1787-1789
Ma Hong-hong, Ma Yan-mei. Analysis of influencing factors of coronary heart disease patients with different insulin resistance [J]. Medical clinical research, 2015, 32(9): 1787-1789
- 王辉宇, 赵光煊. 胰岛素抵抗与冠心病严重程度关系研究 [J]. 中华实用诊断与治疗杂志, 2015, 29(7): 689-691

(下转第 1307 页)

- a Monosodium Iodo-Acetate-Induced Rat Model of Temporomandibular Osteoarthritis [J]. *Oral Maxillofac Surg*, 2016, 74 (5): 927. e1-927
- [5] Hepgulers, Akkoc YS, Pehlivan M, et al. The Efficacy of intraarticular sodium hyaluronate in patients with reducing displaced disc of the temporomandibular joint[J]. *J Oral Rehabil*, 2002, 29(1): 80-86
- [6] Kim TY, Shin JS, Lee J, Lee YJ. Gender Difference in Associations between Chronic Temporomandibular Disorders and General Quality of Life in Koreans:A Cross-Sectional Study [J]. *PLoS One*, 2015, 10 (12): 1-13
- [7] Salash JR, Hossameldin RH, Almarza AJ. Potential Indications for Tissue Engineering in Temporomandibular Joint Surgery [J]. *Oral Maxillofac Surg*, 2016, 74(4): 705-711
- [8] Guarda-Nardini L, Rossi A, Ramonda R. Effectiveness of treatment with viscosupplementation in temporomandibular joints with or without effusion[J]. *Int J Oral Maxillofac Surg*, 2014, 43(10):1218-1223
- [9] Litwiniuk M, Krejner A, Speyrer MS, et al. Hyaluronic acid in inflammation and tissue regeneration[J]. *Wounds*, 2016, 28(3): 78-88
- [10] Xu L, Guo H, Li C, et al. A time-dependent degeneration manner of condyle in rat CFA-induced inflamed TMJ[J]. *Am J Transl Res*, 2016, 8(2): 556-567
- [11] Rahal A, Poirier J, Ahmarani C. Single-puncture arthrocentesis-introducing a new technique and a novel device[J]. *J Oral Maxillofac Surg*, 2009, 67(8): 1771-1773
- [12] Li T, Li G. Effect of articular cavity injection for patients with temporomandibular joint osteoarthritis at different ages [J]. *Shanghai Kou Qiang Yi Xue*, 2015, 24(3): 356-360
- [13] Triantaffilidou K, Venetis G, Bika O. Efficacy of hyaluronic acid injections in patients with osteoarthritis of the temporomandibular joint. A comparative study [J]. *J Craniofac Surg*, 2013, 24 (6): 2006-2009
- [14] Lu HD, Zhao HQ, Wang K, et al. Novel hyaluronic acid-chitosan nanoparticles as non-viral gene delivery vectors targeting osteoarthritis[J]. *Int J Pharm*, 2011, 420(2): 358-365
- [15] Legré-Boyer V. Viscosupplementation: Techniques, indications, results [J]. *Orthop Traumatol Surg Res*, 2015, 101(1Suppl): S101-108
- [16] Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations[J]. *Ther Adv Musculoskelet Dis*, 2013, 5(2): 77-94
- [17] Moreland LW. Intro-articular hyaluronan(hyaluronic acid)and hylans for the treatment of osteoarthritis:mechanisms of action [J]. *Arthritis Res Ther*, 2012, 24(2): 54-67
- [18] Manfredini D, Rancitelli D, Ferronato G, et al. Arthrocentesis with or without additional drugs in temporomandibular joint inflammatory-degenerative disease:comparison of six treatment protocols [J]. *J Oral Rehabil*, 2012, 39(4): 245-251
- [19] Hegab AF, Ali HE, Elmasry M, et al. Platelet-Rich Plasma Injection as an Effective Treatment for Temporomandibular Joint Osteoarthritis[J]. *J Oral Maxillofac Surg*, 2015, 73(9): 1706-1713
- [20] Li C, Long X, Deng M. Osteoarthritic changes after superior and inferior joint space injection of hyaluronic acid for the treatment of temporomandibular joint?osteoarthritis with anterior disc displacement without reduction: a cone-beam computed tomographic evaluation[J]. *J Oral Maxillofac Surg*, 2015, 73(2): 232-244

(上接第 1296 页)

- Wang Hui-yu, Zhao Guang-xuan. Study on the relationship between insulin resistance and coronary heart disease [J]. *Chinese Journal of practical diagnosis and treatment*, 2015, 29(7): 689-691
- [12] Chiadi E, Ndumele Kunihiro, Matsushita Brad, et al. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study [J]. *European journal of preventive cardiology*, 2014, 21(7): 866-75
- [13] Konrad Talbot, Hoau-Yan Wang, Hala Kazi, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline[J]. *J Clin Invest*, 2012, 122(4): 1316-1338
- [14] Shaodong Guo. Insulin Signaling, Resistance, and the Metabolic Syndrome: Insights from Mouse Models to Disease Mechanisms[J]. *J Endocrinol*, 2014, 220(2): T1-T23
- [15] Shuang Mei, Xuefeng Yang, Huailan Guo, et al. A Small Amount of Dietary Carbohydrate Can Promote the HFD-Induced Insulin Resistance to a Maximal Level[J]. *PLoS One*, 2014, 9(7): e100875
- [16] Ilias Stagakis, George Bertsias, Stylianos Karvounaris, et al.

Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance [J]. *Arthritis Res Ther*, 2012, 14 (3): R141

- [17] Peter Willeit, Alexander Thompson, Thor Aspelund, et al. Hemostatic Factors and Risk of Coronary Heart Disease in General Populations: New Prospective Study and Updated Meta-Analyses[J]. *PLoS One*, 2013, 8(2): e55175
- [18] Nadeem Sarwar, Thor Aspelund, Gudny Eiriksdottir, et al. Markers of Dysglycaemia and Risk of Coronary Heart Disease in People without Diabetes: Reykjavik Prospective Study and Systematic Review [J]. *PLoS Med*, 2010, 7(5): e1000278
- [19] Yanwen Qin, Ling Xue, Pingping Jiang, et al. Mitochondrial tRNA Variants in Chinese Subjects With Coronary Heart Disease [J]. *J Am Heart Assoc*, 2014, 3(1): e000437
- [20] Zhou Guangpeng, Zhang Jinglan, Chen Shu, et al. The expression level and clinical significance of adiponectin and insulin receptor in patients with coronary heart disease complicated with type II diabetes [J]. *Western medicine*, 2015, 27(10): 1494-1496